← Back to Compounds
oralandrogen

Androstenediol

5-Androstenediol3β,17β-Androstene-3,17-diol
7
Anabolic Ratio
2
Androgenic Ratio
0.08d
Half-Life

Natural prohormone that converts to testosterone via 3β-HSD. Produced naturally in the adrenal cortex and gonads. Sold briefly as an OTC supplement in the post-DSHEA era (late 1990s). More immune-stimulating effects documented than true anabolic effects. Minimal ergogenic benefit established in human trials. Scheduled III in 2004.

Mechanism of Action

Direct weak AR agonist. Converts to testosterone via 3β-HSD in peripheral tissue. Also has direct ER (estrogen receptor) binding with estrogenic activity. Some immunomodulatory effects (stimulates natural killer cell activity) documented in rodent models — proposed mechanism for reported anti-radiation effects. Effective testosterone conversion rate is low and variable.

Androstenediol molecule
Molecular structure

Typical Dosing

350 mg
low / week
700 mg
moderate / week
1400 mg
high / week

⚠ Warning Flags

  • Schedule III in the US (2004)
  • More estrogenic than androgenic in practice
  • No meaningful anabolic effect documented in humans

Effect Profile

Muscle Protein Synthesis
1Minimal
Nitrogen Retention
1Minimal
Strength Gains
1Minimal
Red Blood Cell Production
1Minimal
Fat Loss
1Minimal
Glycogen Storage
1Minimal
Recovery Speed
2Minimal
Collagen Synthesis
1Minimal

Side Effect Profile

Hormonal Suppression
2Minimal
Estrogenic Effects
3Low
Androgenic Effects
2Minimal
Cardiovascular Strain
1Minimal
Liver Stress
2Minimal
Insulin Resistance
1Minimal
Mood Changes
1Minimal
Prostate Risk
1Minimal

Research Studies

The acute effects of androstenediol supplementation in healthy young males

Ballantyne CS, et al. · 2000

PubMed

Acute androstenediol supplementation produced small and variable testosterone elevation (< 10% above baseline) with significant estradiol increases — estrogenic conversion exceeds androgenic conversion, rendering the prohormone counterproductive for anabolic purposes.